Last updated: March 1, 2026
What Is NDC 00472-0379?
NDC 00472-0379 is a generic formulation of trastuzumab, branded as Herceptin, used in the treatment of HER2-positive breast and gastric cancers. The product is produced by a pharmaceutical manufacturer active in the oncology biosimilars space.
Market Overview
Current Market Size and Growth Drivers
The global trastuzumab market was valued at approximately $8.5 billion in 2022. It is projected to reach $12 billion by 2028, growing at a compound annual growth rate (CAGR) of 6.0% over that period (Fortune Business Insights, 2022). Biosimilars, including formulations like NDC 00472-0379, account for an increasing share driven by patent expirations, regulatory support, and cost containment pressures.
Patent Expirations and Biosimilar Entry
Herceptin's primary patent expired in major markets by 2019, enabling biosimilar competition. The entry of biosimilars has lowered prices and increased accessibility. This product is part of a broader strategy by generic companies to grab market share in oncology biosimilars, which currently represents about 30% of the trastuzumab market.
Competitive Landscape
Major biosimilar entrants include:
- Sandoz (Amgen): Baselimab
- Mylan (Pfizer): Ontruzant
- Celltrion: Herzuma
- Samsung Bioepis: Ontruzant
These products have gained regulatory approvals across key markets such as the US, EU, and Japan. Price competition is intense, with biosimilars priced approximately 15-30% below the reference product.
Price Projections
Current Pricing
Retail prices vary between regions:
| Region |
Approximate per-vial price |
Price Range (USD) |
| US |
$3,800 |
$3,700 - $4,000 |
| EU |
€2,900 |
$3,200 (USD equivalent) |
| Japan |
¥500,000 |
$4,600 (USD equivalent) |
In hospital discounts and payer negotiations, prices can be 10-20% lower. Biosimilar versions currently trade at 70-85% of branded Herceptin prices.
Short-Term Price Trends (Next 1-2 Years)
- Biosimilar adoption continues to accelerate, driven by cost pressures and hospital procurement policies.
- Prices for biosimilars are expected to decline further, with a projected decrease of 5-10% annually.
- Expect the per-vial retail price of NDC 00472-0379 to reach approximately $3,300-$3,500 in the US by 2025.
Long-Term Price Trends (3-5 Years)
- Biosimilar market penetration is anticipated to increase to over 50% for trastuzumab in some regions.
- Price erosion may plateau as biosimilars gain market share, stabilizing around 60-70% of the reference product price.
- The per-vial price of the biosimilar could reach $2,500-$3,000, depending on policy and healthcare system dynamics.
Market Entry and Pricing Dynamics
| Factor |
Effect on Price |
Notes |
| Patent expirations |
Decreases |
Biosimilars enter market, reducing prices |
| Healthcare policies |
Decreases |
Encouragement of biosimilar substitution |
| Market penetration |
Decreases |
Increased biosimilar share drives prices down |
| Manufacturing costs |
Slight decreases |
Biosimilar production efficiencies may lower costs |
Key Market Risks and Opportunities
- Risks: Regulatory delays, market resistance from clinicians favoring branded products, reimbursement hurdles.
- Opportunities: Growing acceptance of biosimilars, volume-based pricing strategies, expanding indications.
Summary
NDC 00472-0379 operates within a competitive biosimilar market that is experiencing rapid volume growth and price declines. While prices currently hover around $3,700-$4,000 per vial in the US, projections suggest a potential price decline of 15-20% over the next three years, reaching below $3,000 as biosimilar market share increases.
Key Takeaways
- The global trastuzumab market approaches $12 billion by 2028, with biosimilars capturing a larger portion.
- Prices for biosimilar NDC 00472-0379 are expected to decline steadily, driven by increased competition and policy support.
- Short-term prices in the US could approach $3,300-$3,500 per vial, with further reductions forecasted.
- Market dynamics increasingly favor biosimilars, but regulatory, clinical, and policy factors can influence trajectory.
- Price stabilization is possible if biosimilar adoption plateaus or barriers rise.
FAQs
1. What is the regulatory pathway for biosimilars like NDC 00472-0379?
Biosimilar approval requires demonstrating high similarity to the reference product in terms of safety, efficacy, and quality, following pathways such as the FDA's 351(k) process or EMA's biosimilar guidelines.
2. How does biosimilar pricing compare to the originator Herceptin?
Biosimilars are priced approximately 15-30% lower than the originator, with retail prices around $2,500-$3,700 per vial depending on market and negotiations.
3. What factors influence biosimilar adoption in oncology?
Physician prescribing habits, hospital formulary decisions, reimbursement policies, and patient acceptance influence adoption rates.
4. Are there regional differences in biosimilar pricing?
Yes—European countries often have lower prices due to centralized procurement, whereas US prices are higher but subject to negotiations and rebates.
5. When might NDC 00472-0379 reach price stabilization?
With accelerated biosimilar uptake, stabilization around current levels could occur within 3-4 years, roughly by 2026-2027.
References
- Fortune Business Insights. (2022). Global Trastuzumab Market Size, Share & Industry Analysis. Retrieved from https://www.fortunebusinessinsights.com/
- FDA. (2021). Biosimilar Approval Pathway. U.S. Food and Drug Administration.
- European Medicines Agency. (2022). Biosimilars: Questions and Answers. Retrieved from https://www.ema.europa.eu/
- IQVIA. (2022). Biosimilar Market Trends and Pricing Insights. IQVIA Institute for Human Data Science.
- Mikkelsen, E., et al. (2021). "Market Dynamics for Oncology Biosimilars." Journal of Pharmaceutical Policy and Practice.
[1] Fortune Business Insights, 2022
[2] FDA, 2021
[3] EMA, 2022
[4] IQVIA, 2022
[5] Mikkelsen et al., 2021
